Tag - ESPR

Markets

HCW starts Esperion at buy; PT $22

H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...

March 10, 2022

Developments

Esperion presents positive Phase 3 NEXLETOL data

Esperion (NASDAQ: ESPR) presented positive pooled results from four Phase 3 NEXLETOL trials at the virtual American Heart Association scientific sessions. NEXLETOL, or bempedoic acid, is a non-statin, low-density...

November 13, 2020

Developments

FDA accepts Esperion NDAs for LDL cholesterol-lowering candidates

The FDA has accepted Esperion’s (NASDAQ:ESPR) NDAs for its bempedoic acid and bempedoic acid-ezetimibe combination tablets for the treatment of elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid and...

May 9, 2019

Tag - ESPR

HCW starts Esperion at buy; PT $22

Esperion presents positive Phase 3 NEXLETOL data

FDA accepts Esperion NDAs for LDL cholesterol-lowering candidates

General

More